|Bid||3.1600 x 1000|
|Ask||3.4800 x 4000|
|Day's range||3.3500 - 3.5000|
|52-week range||2.0600 - 12.6100|
|Beta (5Y monthly)||0.67|
|PE ratio (TTM)||N/A|
|Earnings date||07 Nov 2022 - 11 Nov 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||11.45|
Crenezumab was safe and well tolerated with no cases of ARIA-E observed during the up to eight-year studyAs previously reported, numerical differences favoring crenezumab over placebo were confirmed across the co-primary, multiple secondary and exploratory endpoints, none statistically significantDemographic and baseline biomarker data indicate a confluence of factors which may have caused the study to have lower than expected statistical powerAll mutation carriers may continue to receive crenez
A look at the shareholders of AC Immune SA ( NASDAQ:ACIU ) can tell us which group is most powerful. Institutions will...
AC Immune (ACIU) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?